ELMO2
Engulfment and cell motility protein 2
Protein Summary
Involved in cytoskeletal rearrangements required for phagocytosis of apoptotic cells and cell motility. Acts in association with DOCK1 and CRK. Was initially proposed to be required in complex with DOCK1 to activate Rac Rho small GTPases. May enhance the guanine nucleotide exchange factor (GEF) activity of DOCK1. The protein encoded by this gene interacts with the dedicator of cyto-kinesis 1 protein. Similarity to a C. elegans protein suggests that this protein may function in phagocytosis of apoptotic cells and in cell migration. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2015]
- ENST00000290246
- ENSP00000290246
- ENSG00000062598
- ENST00000372176
- ENSP00000361249
- ENST00000396391
- ENSP00000379673
- CED12A
- KIAA1834
- VMPI
- CED12
- CED-12
- ELMO-2
- Ced-12A
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
disease perturbation | 0.87 | ||
protein domain | 0.85 | ||
cell type or tissue | 0.64 | ||
microRNA | 0.64 | ||
histone modification site profile | 0.63 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 25.77 (req: < 5)
Gene RIFs: 10 (req: <= 3)
Antibodies: 236 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 25.77 (req: >= 5)
Gene RIFs: 10 (req: > 3)
Antibodies: 236 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 8
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0